EXEL stock forecast
Our latest prediction for Exelixis, Inc.'s stock price was made on the May 8, 2019 when the stock price was at 20.32$.
In the short term (2weeks), EXEL's stock price should outperform the market by 0.56%. During that period the price should oscillate between -5.10% and +9.53%.
In the medium term (3months), EXEL's stock price should outperform the market by 0.84%. During that period the price should oscillate between -13.35% and +29.33%.Get email alerts
About Exelixis, Inc.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
At the moment the company generates 910M USD in revenues.
On its last earning announcement, the company reported a profit of 2.04$ per share.
The book value per share is 2.60$
Three months stock forecastMay 8, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|